Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.35 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6396688 | 1.00 | MAP2K1 (0.35) | MAP2K1MAP2K2MAP2K5MAPK1BRAF | |
| SCHEMBL6207841 | 0.87 | MAP2K1 (0.36) | MAP2K1MAP2K2GSK3B | |
| SCHEMBL6191149 | 0.86 | MAP2K1 (0.35) | MAP2K1MAP2K2MAP2K5MAPK1BRAF | |
| SCHEMBL6186912 | 0.86 | MAP2K1 (0.35) | MAP2K1MAP2K2MAP2K5MAPK1BRAF | |
| SCHEMBL6186539 | 0.86 | MAP2K1 (0.48) | MAP2K1MAP2K2MAP2K5MAPK1BRAF | |
| SCHEMBL6188842 | 0.86 | GSK3B (0.33) | MAP2K1MAP2K2MAP2K5MAPK1BRAF | |
| SCHEMBL6189159 | 0.84 | MAP2K1 (0.42) | MAP2K1MAP2K2MAP2K5MAPK1BRAF | |
| SCHEMBL6190111 | 0.84 | MAP2K1 (0.42) | MAP2K1MAP2K2MAP2K5MAPK1BRAF | |
| SCHEMBL6207490 | 0.83 | IRAK4 (0.37) | MAP2K1MAP2K2MAP2K5MAPK1BRAF | |
| SCHEMBL5622768 | 0.80 | MAP2K1 (0.49) | MAP2K1MAP2K2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | MAP2K1 46/4885MAP2K2 40/4885MAP2K5 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.